ATE301112T1 - Triazolone mit neuroprotektiver wirkung - Google Patents
Triazolone mit neuroprotektiver wirkungInfo
- Publication number
- ATE301112T1 ATE301112T1 AT99915760T AT99915760T ATE301112T1 AT E301112 T1 ATE301112 T1 AT E301112T1 AT 99915760 T AT99915760 T AT 99915760T AT 99915760 T AT99915760 T AT 99915760T AT E301112 T1 ATE301112 T1 AT E301112T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- brain
- compound
- formula
- treatment
- Prior art date
Links
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002660 Anoxia Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010021118 Hypotonia Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000007379 Muscle Hypotonia Diseases 0.000 abstract 1
- 206010028923 Neonatal asphyxia Diseases 0.000 abstract 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 201000009941 intracranial hypertension Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000033300 perinatal asphyxia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000005809 status epilepticus Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19816882A DE19816882A1 (de) | 1998-04-17 | 1998-04-17 | Triazolone mit neuroprotektiver Wirkung |
| PCT/EP1999/002498 WO1999054315A2 (de) | 1998-04-17 | 1999-04-14 | Triazolone mit neuroprotektiver wirkung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE301112T1 true ATE301112T1 (de) | 2005-08-15 |
Family
ID=7864724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99915760T ATE301112T1 (de) | 1998-04-17 | 1999-04-14 | Triazolone mit neuroprotektiver wirkung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6492407B2 (enExample) |
| EP (1) | EP1071671B1 (enExample) |
| JP (1) | JP4757382B2 (enExample) |
| AT (1) | ATE301112T1 (enExample) |
| CA (1) | CA2327784C (enExample) |
| DE (2) | DE19816882A1 (enExample) |
| WO (1) | WO1999054315A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613786B2 (en) | 2001-11-02 | 2003-09-02 | Bristol-Myers Squibb Company | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants |
| US7520862B2 (en) | 2004-02-03 | 2009-04-21 | Neuro Diagnostic Devices, Inc. | Cerebral spinal fluid shunt evaluation system |
| DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
| DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| DE102009028929A1 (de) * | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| PL2539326T3 (pl) | 2010-02-27 | 2017-10-31 | Bayer Ip Gmbh | Połączone bis-arylem arylotriazolony i ich zastosowanie |
| DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
| DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
| EP2753179A4 (en) * | 2011-09-09 | 2015-03-04 | Univ Leland Stanford Junior | TOPICAL ITRACONAZOLE FORMULATIONS AND THEIR USE |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| KR20170081178A (ko) | 2014-11-03 | 2017-07-11 | 바이엘 파마 악티엔게젤샤프트 | 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도 |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| TW201945346A (zh) | 2018-04-10 | 2019-12-01 | 德商拜耳廠股份有限公司 | 2,4,5-三取代的1,2,4-三唑酮之製備方法 |
| US12194026B2 (en) | 2018-10-26 | 2025-01-14 | University Of South Florida | Drug for treating tinnitus |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1311651A (en) * | 1969-05-08 | 1973-03-28 | Gold Aubert P | Salts of delta2-1,2,4-triazolin-5-one derivatives |
| JPS5653662A (en) * | 1979-10-08 | 1981-05-13 | Nippon Nohyaku Co Ltd | Preparation of delta2-1,2,4-triazolin-5-ones |
| JPS58225070A (ja) * | 1982-06-23 | 1983-12-27 | Nippon Nohyaku Co Ltd | Δ↑２−１，２，４−トリアゾリン−５−オン誘導体及び製法並びにその用途 |
| GB8429307D0 (en) * | 1984-11-20 | 1984-12-27 | Shell Int Research | Heterocyclic herbicides |
| ZA865000B (en) * | 1985-07-12 | 1987-02-25 | Hoffmann La Roche | Heterocyclic compounds |
| DK570987A (da) * | 1986-12-01 | 1988-06-02 | Hoffmann La Roche | Oxadiazol-, thiadiazol- og triazolforbindelser |
| JP2593084B2 (ja) * | 1986-12-19 | 1997-03-19 | メレルダウファーマスーティカルズ インコーポレーテッド | ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途 |
| US5436252A (en) * | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| PH24094A (en) * | 1986-12-19 | 1990-03-05 | Merrell Dow Pharma | 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants |
| DK35688A (da) * | 1987-01-27 | 1988-07-28 | Merrell Dow Pharma | Fremgangsmaade til fremstilling af 5-aryl-2,4-diakyl-3h-1,2,4-triazol-3-thioner |
| US5120347A (en) * | 1990-06-21 | 1992-06-09 | Rohm And Haas Company | Aryl triazole herbicides |
| US5256793A (en) * | 1992-05-13 | 1993-10-26 | Fmc Corporation | Triazolinone ring formation in tert-butanol |
| IT1256387B (it) * | 1992-11-13 | 1995-12-04 | Acraf | Procedimento per preparare triazoloni |
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| DE69615376T2 (de) * | 1995-07-13 | 2002-09-05 | Knoll Gmbh | Piperazin-derivate als heilmittel |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| US5756755A (en) * | 1996-08-26 | 1998-05-26 | Fmc Corporation | Difluoromethylation of 4,5-dihydro-1-phenyl-3-methyl-1,2,4-triazol-5(1H)-ones with glymes as solvents |
-
1998
- 1998-04-17 DE DE19816882A patent/DE19816882A1/de not_active Withdrawn
-
1999
- 1999-04-14 AT AT99915760T patent/ATE301112T1/de not_active IP Right Cessation
- 1999-04-14 WO PCT/EP1999/002498 patent/WO1999054315A2/de not_active Ceased
- 1999-04-14 EP EP99915760A patent/EP1071671B1/de not_active Expired - Lifetime
- 1999-04-14 CA CA002327784A patent/CA2327784C/en not_active Expired - Fee Related
- 1999-04-14 JP JP2000544654A patent/JP4757382B2/ja not_active Expired - Fee Related
- 1999-04-14 DE DE59912358T patent/DE59912358D1/de not_active Expired - Lifetime
-
2001
- 2001-04-23 US US09/840,281 patent/US6492407B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6492407B2 (en) | 2002-12-10 |
| DE19816882A1 (de) | 1999-10-21 |
| JP2002512236A (ja) | 2002-04-23 |
| JP4757382B2 (ja) | 2011-08-24 |
| US20020045651A1 (en) | 2002-04-18 |
| WO1999054315A3 (de) | 1999-12-29 |
| EP1071671B1 (de) | 2005-08-03 |
| EP1071671A2 (de) | 2001-01-31 |
| WO1999054315A2 (de) | 1999-10-28 |
| CA2327784A1 (en) | 1999-10-28 |
| CA2327784C (en) | 2008-03-18 |
| DE59912358D1 (de) | 2005-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE59912358D1 (de) | Triazolone mit neuroprotektiver wirkung | |
| TW200642685A (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| CA2400778A1 (en) | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | |
| TNSN05165A1 (fr) | Derives de pyrrolopyrimidine | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| DE60234345D1 (de) | Verbindungen mit taxol-verstärkender wirkung | |
| NL300176I2 (nl) | Esters van 5-aminolevulinezuur als fotosensibiliserende middelen in de fotochemotherapie. | |
| WO2000049007A8 (en) | Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s | |
| MY143051A (en) | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | |
| NZ539841A (en) | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | |
| CA2336909A1 (en) | Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity | |
| RU94036772A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| WO2009040331A3 (en) | Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies | |
| IL107134A0 (en) | Pharmaceutical compositions for the treatment of parkinson's disease | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| WO2002089782A3 (en) | Dioxanes and uses thereof | |
| NO306509B1 (no) | Pyrimidinderivater, anvendelse derav og farmasöytisk preparat | |
| IL165181A0 (en) | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
| DE602004016850D1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| SI1968571T1 (sl) | Uporaba benzo kondenziranih heterocikličnih sulfamidnih derivatov kot nevroprotektivnih sredstev | |
| DE60330356D1 (en) | Stickstoff-lost-derivaten | |
| TW200639159A (en) | Treatment of pain | |
| WO2006050861A3 (en) | Statine derivatives for the treatment of alzheimer's disease | |
| RU94031479A (ru) | Новое применение производных аминокислот, способ лечения, фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |